Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Early Impact of Nirsevimab on Ambulatory All-Cause Bronchiolitis: A Prospective Multicentric Surveillance Study in France.

Corinne Levy,Andreas Werner,Alexis Rybak,Stéphane Béchet,Christophe Batard,Frédéric Hassid, Roxane Desandes,Bruno Frandji,Naim Ouldali, Robert Cohen

Journal of the Pediatric Infectious Diseases Society（2024）

Cited 0|Views13
No score
Abstract
After implementation of nirsevimab in 2023 in France as compared with 2022-2023, we found a 52.7%, 95% CI [46.4-58.9]) decrease in all-cause bronchiolitis in children <3 months with the lowest number of bronchiolitis cases in this population since 2017.
More
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined